Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2013 | 02:40pm CEST
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | [email protected]

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | [email protected]
Zogenix
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
09:59p KEITH ROTHFUS : Rothfus Leads Bipartisan and Bicameral Letter Supporting Western Pennsylvania’s Locks and Dams
09:59p DGAP-NVR : MorphoSys AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 26a WpHG mit dem Ziel der europaweiten Verbreitung
09:59p DGAP-NEWS : bmp Holding AG: Veröffentlichung Geschäftsbericht 2016
09:59p Swank Capital and Cushing® Asset Management Announce a Constituent Change to The Cushing® MLP Market Cap Index
09:59p SBERBANK ROSSII : participates in discussion of the State Programme to Develop Russia’s Digital Economy
09:58p IMMUNE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
09:58p Faxitron Announces LOCalizer™ Radiofrequency Identification System Granted FDA 510(k) Clearance for Use in Breast Lesion Localization
09:57p KERR MINES : Town councilman's emails on mining cause flap
09:57p BIONEUTRA GLOBAL CORPORATION : Reports Fiscal Year Ended December 31, 2016 Financial Results
09:57p Swank Capital and Cushing® Asset Management Announce a Constituent Change to the Cushing® MLP High Income Index
Latest news
Advertisement
Hot News 
5.37%AIR BERLIN : Restructuring costs drive Air Berlin to record loss
5.43%REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects for eczema drug
-4.13%INTEL : revenue misses estimates as data centre growth slows
4.24%Google parent Alphabet's profit up 29 percent on strong ad sales
-3.79%SCHWEIZERISCHE NATIONALBANK : Swiss central bank shareholders lose battle over dividend hike
Most Read News
06:33a NEXT BATTLEGROUND : An aging Great Lakes pipeline stirs new protest
11:49a TSX rises as resource stocks lead bounce
04/27 Google parent Alphabet's profit up 29 percent on strong ad sales
04/27 Amazon revenue soars as cloud, retail businesses dominate
02:42p Apple, Tesla ask California to change its proposed self-driving car testing policies
Most recommended articles
04/27 JPMorgan Chase & Co leaves blockchain consortium R3
04/21 TWENTY FIRST CENTURY FOX : Government extends period for regulators to report on Sky-Fox merger
03:45pDJQualcomm Warns of Lower Profit as Apple Dispute Bites -- 2nd Update
03:36p Euro gains on European inflation data, dollar jumps against yen
03:36pDJWILMAR INTERNATIONAL : Sugar Surges as Five Companies Take 1.5 Million Tons Off Exchange